NO20083928L - Anvendelse av TPO-peptidforbindelser og farmasoytiske sammensetninger i behandling av anemi - Google Patents

Anvendelse av TPO-peptidforbindelser og farmasoytiske sammensetninger i behandling av anemi

Info

Publication number
NO20083928L
NO20083928L NO20083928A NO20083928A NO20083928L NO 20083928 L NO20083928 L NO 20083928L NO 20083928 A NO20083928 A NO 20083928A NO 20083928 A NO20083928 A NO 20083928A NO 20083928 L NO20083928 L NO 20083928L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
tpo peptide
anemia
treatment
peptide compounds
Prior art date
Application number
NO20083928A
Other languages
English (en)
Other versions
NO341872B1 (no
Inventor
Brian R Macdonald
Edward J Yurkow
Jeffery K Weis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20083928L publication Critical patent/NO20083928L/no
Publication of NO341872B1 publication Critical patent/NO341872B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En metode for behandling av anemi er fremlagt. Metoden inkluderer administrering av en TPO-peptidforbindelse til et subjekt. Farrnasøytiske sammensetninger som inkluderer en TPO- peptidforbindelse og en farmasøytisk akseptabel bærer. · Diagnosemetoder som anvender en merket TPO-peptidforbindelse fremlegges også.
NO20083928A 2006-02-14 2008-09-15 Anvendelse av TPO-peptidforbindelser og farmasøytiske sammensetninger i behandling av anemi NO341872B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/005322 WO2007094781A1 (en) 2006-02-14 2006-02-14 Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia

Publications (2)

Publication Number Publication Date
NO20083928L true NO20083928L (no) 2008-09-15
NO341872B1 NO341872B1 (no) 2018-02-12

Family

ID=37904365

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083928A NO341872B1 (no) 2006-02-14 2008-09-15 Anvendelse av TPO-peptidforbindelser og farmasøytiske sammensetninger i behandling av anemi

Country Status (18)

Country Link
EP (1) EP1984014B1 (no)
JP (1) JP2009526841A (no)
CN (1) CN101374540B (no)
AU (1) AU2006338308B2 (no)
BR (1) BRPI0621347B8 (no)
CA (1) CA2642389C (no)
CY (1) CY1115629T1 (no)
DK (1) DK1984014T3 (no)
EA (1) EA015562B1 (no)
ES (1) ES2516649T3 (no)
IL (1) IL193268A (no)
NI (1) NI200800216A (no)
NO (1) NO341872B1 (no)
NZ (1) NZ570124A (no)
PL (1) PL1984014T3 (no)
PT (1) PT1984014E (no)
SI (1) SI1984014T1 (no)
WO (1) WO2007094781A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10358422B3 (de) 2003-08-26 2005-04-28 Muehlbauer Ag Verfahren zur Herstellung von Modulbrücken
ES2729622T3 (es) * 2008-06-03 2019-11-05 Janssen Pharmaceutica Nv Péptido mimético de TPO para prevenir el desorden hematológico asociado al tratamiento contra el cáncer
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
AU2018306329B8 (en) 2017-07-26 2025-02-20 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
WO2020154637A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
EP3914286B1 (en) 2019-01-25 2025-05-07 Janssen Pharmaceutica NV Methods of mitigating toxic effects of vesicants and caustic gas
MX2021008943A (es) 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos.
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723456A1 (en) * 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
ES2781475T3 (es) * 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
SG131110A1 (en) * 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors

Also Published As

Publication number Publication date
NO341872B1 (no) 2018-02-12
CA2642389C (en) 2014-05-06
NZ570124A (en) 2011-05-27
HK1129571A1 (en) 2009-12-04
EA200870261A1 (ru) 2009-02-27
HK1125055A1 (en) 2009-07-31
PT1984014E (pt) 2014-11-13
BRPI0621347A2 (pt) 2011-12-06
AU2006338308B2 (en) 2012-11-01
SI1984014T1 (sl) 2014-12-31
EP1984014A1 (en) 2008-10-29
DK1984014T3 (da) 2014-09-15
IL193268A0 (en) 2009-02-11
JP2009526841A (ja) 2009-07-23
CN101374540A (zh) 2009-02-25
EA015562B1 (ru) 2011-08-30
ES2516649T3 (es) 2014-10-31
CN101374540B (zh) 2013-03-06
CY1115629T1 (el) 2017-01-04
EP1984014B1 (en) 2014-08-06
PL1984014T3 (pl) 2015-02-27
CA2642389A1 (en) 2007-08-23
WO2007094781A1 (en) 2007-08-23
BRPI0621347B8 (pt) 2021-05-25
IL193268A (en) 2015-02-26
NI200800216A (es) 2012-01-24
BRPI0621347B1 (pt) 2018-05-08
AU2006338308A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
NO20083928L (no) Anvendelse av TPO-peptidforbindelser og farmasoytiske sammensetninger i behandling av anemi
WO2007008257A3 (en) Method and apparatus for delivering epinephrine
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
UA115131C2 (uk) Сполуки боронатного ефіру і його фармацевтичні рецептури
ECSP088762A (es) Tratamiento del dolor
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
AR047928A1 (es) Derivados de tetrahidropiridoindol
MX374396B (es) Rocio de fentanilo sublingual.
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
DE602006012322D1 (de) Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
MX2010002178A (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico.
NO20072290L (no) Organiske forbindelser.
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
WO2007136910A3 (en) Eimmunotherapy for immune suppressed patients
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees